← Back to Clinical Trials
Recruiting NCT06938100

NCT06938100 Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASIL

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06938100
Status Recruiting
Phase
Sponsor Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Condition CADASIL
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-11-21
Primary Completion 2027-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-11-21 with a primary completion date of 2027-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The project aims to retrospectively and prospectively analyze a population of CADASIL patients in order to study the natural history of the disease by correlating the symptom spectrum with genetic risk and specific neuroradiological and biological markers \- Stratifying patients according to their disease risk, this could contribute to the discovery of personalized therapeutic targets.

Eligibility Criteria

Inclusion criteria: * patients of either sex older than 18 years of age; * finding of a pathogenic mutation on genetic analysis of NOTCH3; * in the absence of unambiguous mutation, presence of characteristic deposits (GOM) within small vessels at skin biopsy Exclusion criteria: * do not meet the diagnostic criteria of CADASIL; * are unable to give consent for the study due to aphasic or cognitive impairment or because they are deceased at the time of enrollment and their next of kin refuse to give consent for study participation.

Contact & Investigator

Central Contact

Anna Bersano, MD

✉ anna.bersano@istituto-besta.it

📞 + 39 02.2394

Frequently Asked Questions

Who can join the NCT06938100 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying CADASIL. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06938100 currently recruiting?

Yes, NCT06938100 is actively recruiting participants. Contact the research team at anna.bersano@istituto-besta.it for enrollment information.

Where is the NCT06938100 trial being conducted?

This trial is being conducted at Milan, Italy, Madrid, Spain.

Who is sponsoring the NCT06938100 clinical trial?

NCT06938100 is sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology